Abstract:The glycosphingolipid alpha-galactosylceramide (alpha-GalCer) is a well- described immune activator with strong anti-tumor properties in animal models. It is presented on CD1d and acts by stimulating the invariant, type I, natural killer T (iNKT) lymphocytes to rapidly secrete TH1 and TH2 associated cytokines. This in turn promotes activation of a diversity of immune cells including natural killer (NK) cells with anti-tumor functions. Prior to tumor development, iNKT cells can also perform tumor surveillance and naturally protect from emergence of cancer. In contrast, we have recently demonstrated that iNKT cells naturally promote polyps in the spontaneous murine adenomatous polyposis coli (Apc) Apc(Min/+) model for colon cancer, associated with suppressed TH1 immunity and enhanced immunoregulation. Here we investigated whether iNKT cell directed immunotherapy could subvert the polyp promoting function of iNKT cells and reduce polyp growth in this model. We treated Apc(Min/+) mice with alpha-GalCer, or synthetic derivatives of this ligand (C-glycoside and C20:2) that have enhanced immunoregulatory properties. Treatment with iNKT cell ligands led to increased iNKT cell division, but reduced iNKT cell frequencies, lower NK1.1 expression and elevation of PD-1. Apc(Min/+) mice that had been treated either long-term (5-15 weeks of age), or short-term (12-15 weeks of age) with alpha-GalCer demonstrated a significant decrease in polyp burden. Surprisingly, long-term treatment with the TH1 biasing ligand C-glycoside did not have significant effects on polyps, while long-termtreatment with the TH2 biasing ligand C20: 2 enhanced polyp growth. In stark contrast, short-term treatment with C20: 2 led to reduction in polyp numbers and size. Reduced polyp burden after long-term treatment was associated with increased expression of genes indicating a pro-inflammatory polyp microenvironment. Polyp-reducing short-term treatment led to CD8 T cell activation specifically in polyps, and decreased tumor infiltrating and splenic macrophages, and a switch toward a pro-inflammatory phenotype. Thus, iNKT cell directed therapy could subvert the natural polyp enhancing function of iNKT cells, overcome immunosuppression, and reduce polyps. However, different iNKT cell activating ligands had opposite effects, and the timing of treatment had a major influence on outcomes.

Ligand-Dependent Induction of Noninflammatory Dendritic Cells by Anergic Invariant Nkt Cells Minimizes Autoimmune Inflammation

Combined Proinflammatory Cytokine and Cognate Activation of Invariant Natural Killer T Cells Enhances Anti-Dna Antibody Responses.

Natural Killer Cells Modulate Overt Autoimmunity to Homeostasis in Nonobese Diabetic Mice after Anti-CD3 F(ab′)2 Antibody Treatment through Secreting Transforming Growth Factor-β

Invariant Natural Killer T Cells Regulate Conventional Dendritic Cell Maturation to Re-establish Immune Tolerance to Rheumatoid Arthritis in DBA/1 Mice

Cooperation of Invariant NKT Cells and CD4+CD25+ T Regulatory Cells in the Prevention of Autoimmune Myasthenia

Regulation of Activated Cd4(+) T Cells by Nk Cells Via the Qa-1-Nkg2a Inhibitory Pathway

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

NKG2D Enhances Double-Negative T Cell Regulation of B Cells

Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment

Promotion or Suppression of Murine Intestinal Polyp Development by Inkt Cell Directed Immunotherapy

Enterogenous Bacterial Glycolipids Are Required for the Generation of Natural Killer T Cells Mediated Liver Injury

Activation of Invariant NKT cells with glycolipid ligand α-galactosylceramide ameliorates glucose-6-phosphate isomerase peptide-induced arthritis

Alpha-lactosylceramide as a novel "sugar-capped" CD1d ligand for natural killer T cells: biased cytokine profile and therapeutic activities.

Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity

TLR9-mediated dendritic cell activation uncovers mammalian ganglioside species with specific ceramide backbones that activate invariant natural killer T cells

CD8+NKT-like Cells Regulate the Immune Response by Killing Antigen-Bearing DCs

Canonical Wnt Signaling in Dendritic Cells Regulates Th1/Th17 Responses and Suppresses Autoimmune Neuroinflammation.

Invariant Nkt Cells Act As An Adjuvant To Enhance Th2 Inflammatory Response In An Ova-Induced Mouse Model Of Asthma

Reduced Self-Reactivity of an Autoreactive T Cell After Activation with Cross-reactive Non–Self-Ligand

Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy.

Mechanisms of NKT Cell Anergy Induction Involve Cbl-b-promoted Monoubiquitination of CARMA1